Amygdala Activation and Connectivity to Emotional Processing Distinguishes Asymptomatic Patients With Bipolar Disorders and Unipolar Depression.


Journal

Biological psychiatry. Cognitive neuroscience and neuroimaging
ISSN: 2451-9030
Titre abrégé: Biol Psychiatry Cogn Neurosci Neuroimaging
Pays: United States
ID NLM: 101671285

Informations de publication

Date de publication:
04 2019
Historique:
received: 01 06 2018
revised: 06 08 2018
accepted: 18 08 2018
pubmed: 22 10 2018
medline: 30 1 2020
entrez: 22 10 2018
Statut: ppublish

Résumé

Mechanistically based neural markers, such as amygdala reactivity, offer one approach to addressing the challenges of differentiating bipolar and unipolar depressive disorders independently from mood state and acute symptoms. Although emotion-elicited amygdala reactivity has been found to distinguish patients with bipolar depression from patients with unipolar depression, it remains unknown whether this distinction is traitlike and present in the absence of an acutely depressed mood. We addressed this gap by investigating patients with bipolar disorder (BP) and unipolar major depressive disorder (MDD) in remission. Supraliminal and subliminal processing of faces exhibiting threat, sad, happy, and neutral emotions during functional magnetic resonance imaging was completed by 73 participants (23 BP patients and 25 MDD patients matched for age and gender, number of depressive episodes and severity; 25 age- and gender-matched healthy control subjects). We compared groups for activation and connectivity for the amygdala. BP patients had lower left amygdala activation than MDD patients during supraliminal and subliminal threat, sad, and neutral emotion processing and for subliminal happy faces. BP patients also exhibited lower amygdala connectivity to the insula and hippocampus for threat and to medial orbitofrontal cortex for happy supraliminal and subliminal processing. BP patients also demonstrated greater amygdala-insula connectivity for sad supraliminal and subliminal face processing. Both patient groups were distinct from control subjects across several measures for activation and connectivity. Independent of valence or level of emotional awareness, amygdala activation and connectivity during facial emotion processing can distinguish BP patients and MDD patients. These findings provide evidence that this neural substrate could be a potential trait marker to differentiate these two disorders largely independent of illness state.

Sections du résumé

BACKGROUND
Mechanistically based neural markers, such as amygdala reactivity, offer one approach to addressing the challenges of differentiating bipolar and unipolar depressive disorders independently from mood state and acute symptoms. Although emotion-elicited amygdala reactivity has been found to distinguish patients with bipolar depression from patients with unipolar depression, it remains unknown whether this distinction is traitlike and present in the absence of an acutely depressed mood. We addressed this gap by investigating patients with bipolar disorder (BP) and unipolar major depressive disorder (MDD) in remission.
METHODS
Supraliminal and subliminal processing of faces exhibiting threat, sad, happy, and neutral emotions during functional magnetic resonance imaging was completed by 73 participants (23 BP patients and 25 MDD patients matched for age and gender, number of depressive episodes and severity; 25 age- and gender-matched healthy control subjects). We compared groups for activation and connectivity for the amygdala.
RESULTS
BP patients had lower left amygdala activation than MDD patients during supraliminal and subliminal threat, sad, and neutral emotion processing and for subliminal happy faces. BP patients also exhibited lower amygdala connectivity to the insula and hippocampus for threat and to medial orbitofrontal cortex for happy supraliminal and subliminal processing. BP patients also demonstrated greater amygdala-insula connectivity for sad supraliminal and subliminal face processing. Both patient groups were distinct from control subjects across several measures for activation and connectivity.
CONCLUSIONS
Independent of valence or level of emotional awareness, amygdala activation and connectivity during facial emotion processing can distinguish BP patients and MDD patients. These findings provide evidence that this neural substrate could be a potential trait marker to differentiate these two disorders largely independent of illness state.

Identifiants

pubmed: 30343134
pii: S2451-9022(18)30236-2
doi: 10.1016/j.bpsc.2018.08.012
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

361-370

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2018 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Auteurs

Mayuresh S Korgaonkar (MS)

Brain Dynamics Centre, Westmead Institute for Medical Research, The University of Sydney, New South Wales, Australia; Discipline of Psychiatry, University of Sydney School of Medicine, New South Wales, Australia. Electronic address: M.Korgaonkar@sydney.edu.au.

May Erlinger (M)

Brain Dynamics Centre, Westmead Institute for Medical Research, The University of Sydney, New South Wales, Australia.

Isabella A Breukelaar (IA)

Brain Dynamics Centre, Westmead Institute for Medical Research, The University of Sydney, New South Wales, Australia.

Philip Boyce (P)

Discipline of Psychiatry, University of Sydney School of Medicine, New South Wales, Australia.

Philip Hazell (P)

Discipline of Psychiatry, University of Sydney School of Medicine, New South Wales, Australia.

Cassandra Antees (C)

Brain Dynamics Centre, Westmead Institute for Medical Research, The University of Sydney, New South Wales, Australia.

Sheryl Foster (S)

Department of Radiology, Westmead Hospital, Westmead, New South Wales, Australia; Discipline of Medical Radiation Sciences, Faculty of Health Science, The University of Sydney, New South Wales, Australia.

Stuart M Grieve (SM)

Sydney Translational Imaging Laboratory, Heart Research Institute, Charles Perkins Centre and University of Sydney School of Medicine, New South Wales, Australia; Department of Radiology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.

Lavier Gomes (L)

Department of Radiology, Westmead Hospital, Westmead, New South Wales, Australia.

Leanne M Williams (LM)

Brain Dynamics Centre, Westmead Institute for Medical Research, The University of Sydney, New South Wales, Australia; Psychiatry and Behavioral Sciences, Stanford University, Stanford, Palo Alto, California; Sierra-Pacific Mental Illness Research, Education, and Clinical Center, Palo Alto Veterans Affairs Health Care System, Palo Alto, California.

Anthony W F Harris (AWF)

Brain Dynamics Centre, Westmead Institute for Medical Research, The University of Sydney, New South Wales, Australia; Discipline of Psychiatry, University of Sydney School of Medicine, New South Wales, Australia.

Gin S Malhi (GS)

Discipline of Psychiatry, University of Sydney School of Medicine, New South Wales, Australia; Clinical Assessment Diagnostic Evaluation (CADE) Clinic, Department of Psychiatry, Royal North Shore Hospital, Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH